To investigate the value of imaging-pathology fusion guided targeted cryoablation for localized prostate cancer.

Between June 2014 and February 2017, 64 patients undergoing targeted cryoablation for localized prostate cancer were retrospectively collected and analyzed. The average age was 77.8 years old, ranging 45-87 years old. The preoperative value of PSA ranged from 5.1 to 19.8ng/ml, with mean of 15.3 ng/ml, including 6 case of cT_1c, 35 cases of cT_2a, and 23 cases of cT_2b, and 35 cases of Gleason score 6, 8 cases of 3+ 4 and 21 cases of 4+ 3. All patients had good continence and 11 cases had good erectile function before operation. All the patients received MRI or contrast-enhanced ultrasonography examinations before biopsies, and the sites and range of cryoablation were determined by MRI or contrast-enhanced ultrasonography and biopsy pathological results.

All the patients underwent the surgery successfully. The average postoperative hospital stay was 1.6 days, ranging 1 to 3 days, including 22 cases discharged within 24 h after surgery. The operative duration ranged from 85 to 152 min, with mean of 99.6 min. The satisfaction rate of the patients was 100%. Seven patients had Clavien Ⅰ or Ⅱ postoperative complications, and recovered after symptomatic treatment. The follow-up duration ranged from 0.5 to 32.2 months, with median of 11.8 months. All patients were alive without new metastasis. Eight patients developed biochemical recurrence, 5 of those underwent intermittent endocrine therapy, resulting in stable PSA levels.

Imaging-pathology fusion guided targeted cryoablation was safe and effective for localized prostate cancer with the advantages of few complications, high satisfaction rate and quick recovery.

Prostatic neoplasms; Cryoablation; Targeted; Imaging